✦ LIBER ✦

Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial

✍ Scribed by Frasci, Giuseppe; Lorusso, Vito; Panza, Nicola; Comella, Pasquale; Nicolella, Gianpaolo; Bianco, Andrea; DeCataldis, Giuseppe; Belli, Mario; Iannelli, Nunzio; Massidda, Bruno; Mascia, Vittorio; Comella, Giuseppe; De Lena, Mario

Book ID: 118570698
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 151 KB
Volume: 34
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(01)00392-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine + vinorelbine (GV) yields be

Gemcitabine + vinorelbine (GV) yields better survival than vinorelbine (V) alone in elderly non-small cell lung cancer (NSCLC) patients. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

✍ Frasci, G; Lorusso, V; Panza, N; Comella, P; De Cataldis, G; Micillo, E; Iannell 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Cisplatin-gemcitabine, vs. cisplatin-gem

Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

✍ Comella, P; Frasci, G; Panza, N; Nicolella, G; Manzione, L; De Cataldis, G; Ciof 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Interim Analysis of a Phase III Trial Co

Interim Analysis of a Phase III Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine vs. Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer. A Southern Italy Cooperative Oncology Group Study

✍ Pasquale Comella; Nicola Panza; Luigi Manzione; Giuseppe De Cataldis; Riccardo C 📂 Article 📅 2000 🏛 CIG Media Group, LP. 🌐 English ⚖ 440 KB

P.40 Oral vinorelbine and gemcitabine (o

P.40 Oral vinorelbine and gemcitabine (oVG) versus docetaxel and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis for elderly patients of a phase III randomized trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Karampeazis, A.; Agelaki, S.; Agelidou, A.; Kotsakis, A.; Kakolyri 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB